Clinical Trial Update: Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravitreal anti-VEGF therapy as initial and adjuvant treatment for Coats disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coats Disease
• Retinal Telangiectasia

Drugs mentioned

• Anti-VEGF intravitreal injections

Snippet

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Conditions: Retinal Telangiectasis, Coats Disease | Phase 3 | Status: TERMINATED